Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data by CNBC Markets | August 19, 2025 7:14 pm | US Markets The results could reinforce Eli Lilly and Novo Nordisk’s dominance in the booming market for weight loss and diabetes drugs.
